<DOC>
	<DOCNO>NCT00499551</DOCNO>
	<brief_summary>The multiple property corticosteroids inflammatory response , make first line drug treatment several ocular inflammatory disorder different etiology . In order diminish corticosteroid severe systemic adverse effect , local administration prefer . Iontophoresis already use successful way administration corticosteroid . Clinical histopathological injury due use transcleral CCI observe . successful administration methylprednisolone mean system previous study . The objective evaluate tolerance , security effectiveness treatment , use new generation device .</brief_summary>
	<brief_title>A Phase I/IIa Study Treatment Uveitis With Iontophoresis</brief_title>
	<detailed_description>The multiple property corticosteroids inflammatory response , make first line election treatment several ocular inflammatory disorder different etiology . Within property mention : reestablishment vascular permeability , decrease cellular infiltrate exudation fibrin , alteration activity monocytes neutrophil , decrease proliferation fibroblasts endothelial cell diminish neovascularization post inflammation ( 1 ) . For reason , diminish inflammatory reaction , also diminish formation permanent scar , often responsible visual loss ( 2,3 ) . The severe systemic adverse effect corticosteroid : systemic hyperglicemy , formation gastric ulcer , avascular necrosis head femur , suppression hypothalamus-pituitary adrenal axis , arterial hypertension among others ( 21,22 ) . In order diminish severe systemic adverse effect corticosteroid , local administration prefer ( 4 ) . The subconjunctival injection topical instillation , reach effective concentration anterior chamber ( 5-7 ) whereas reach concentration posterior segment require systemic , intravitreous periocular administration ( 8-11 ) . Generally require multiple injection , produce patient discomfort . In addition , periocular administration , small fraction drug penetrate eye , whereas rest systemically absorb , reason systemic adverse effect avoid . Iontophoresis already successful use administration corticosteroid , reach high lasting concentration segment eye . ( 12-13 ) . Remaining effective concentration 40 60 hour administration ( 23 ) . But , Because focal chorioretinal injury describe , use transcleral Iontophoresis , use current high density ( 14-18 ) , method gain space current clinical practice . It previously demonstrate Controlled Column Iontophoresis ( CCI Eyegate , Optis France SA ) effective intraperitoneal administration Dexamethasone treatment anterior posterior uveitis induce endotoxin ( 19 ) . Through control electrical parameter use safer setting , clinical histopathological injury due use transcleral CCI observe ( 20 ) . The result pre-clinical study , methylprednisolone succinate mean CCI administer , demonstrate safe method , report high last intraocular concentration . In addition , study France elaborate , include 89 patient different intraocular inflammatory disease . Such corneal graft rejection , previous uveitis , postoperative endophthalmitis , macular edema inflammation posterior segment . For evaluation security effectiveness administration methylprednisolone mean CCI . The patient enlist required periocular systemic treatment due failure maximal topical therapy . The average treatment Iontophoresis 2,7 +/- 0,9 ( 1-5 ) , current intensity 1,2 2mA duration 2 5 minute treatment . A significant increase conjunctival hyperemia observe , subsequent CCI , spontaneous resolve . There related adverse Effects . Still , observed increase visual acuity decrease clinical inflammation group patient . No patient loss vision inflammation biomarkers , take like whole , continue improve 30 day treatment .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<criteria>Clinical history , noneinfectious anterior , intermediate , posterior panuveitis , without associate systemic disease , like : Vogt Koyanagi Harada , Wegener Granulomatosis , Systemic erythematous Lupus , Beh√ßet disease , etc . Requirement current topical treatment steroid ( every 6 hour ) , need acute chronic treatment oral , intravenous , periocular intravitreous corticosteroid immunosuppressive agent control disease . Best Corrected Visual Acuity bad eye 20/40 20/800 ETDRS record . Patients good mydriasis significant ocular opacity . Patients plan elective surgery . Infectious , postraumatic , Fuchs selflimited uveitis . Patients Diagnosis glaucoma ocular hypertension ( great 25mmHg ) . Diagnosis suspect ocular central nervous system lymphoma . Patients one eye . Associated optical Neuritis etiology . Severe injury eyelids ocular surface prevent application electrode . Wellknown allergy Dexamethasone . Toxoplasma scar vitreous hemorrhage . Corneal injuries herpetic origin suspicion herpetic . Patients poor mydriasis , significant ocular opacity prevents evaluation posterior pole followup study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Anterior Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Panuveitis</keyword>
	<keyword>Iontophoresis</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>